September 22, 2014 3:23 PM ET

Biotechnology

Company Overview of Cellectis Plant Sciences Inc

Company Overview

Cellectis Plant Sciences Inc operates as a subsidiary of Cellectis.

1000 Westgate Drive

Suite 101

St Paul, MN 55114

United States

Key Executives for Cellectis Plant Sciences Inc

Chief Executive Officer
Compensation as of Fiscal Year 2014.

Cellectis Plant Sciences Inc Key Developments

Cellectis Plant Sciences and Bayer CropScience Extend Partnership to Improve Crops by Gene Editing

Cellectis plant sciences has signed two new agreements with Bayer CropScience on gene editing in plants. The agreements extend the companies' existing partnership to introduce targeted modifications to selected plant genes and genomes. The first aim of this extended partnership is to collaboratively create commercial traits for the canola seed market using new technologies developed by Cellectis plant sciences. The second aim is to provide Bayer with access to technologies that enable the directed engineering of plant genomes, such as gene stacking and targeted mutagenesis, for the development of improved crops.

Medicago and Cellectis Successfully Achieve First Step in Research Collaboration

Medicago Inc. and Cellectis Plant Sciences Inc, announced the successful completion of the first step in their research collaboration to improve therapeutic proteins produced in tobacco plants. As part of an ongoing effort in the development biosimilar protein therapeutics from tobacco plants, Medicago is partnering with Cellectis to modify the glycosylation of biosimilar product candidates. A biosimilar product is a therapeutic protein, which is similar in terms of quality, safety and efficacy to an already approved and marketed biotherapeutic product. Glycosylation is the addition of sugar molecules to proteins. Modifying the glycosylation of a protein can optimize the efficacy and other characteristics such as solubility, therapeutic half-life, and tissue distribution. Cellectis develops enzymes called nucleases that can specifically cut DNA and modify genes, and can enable the modification of protein glycosylation patterns. These nucleases can enable the development of modified tobacco plants with the goal of producing biosimilar products with optimal efficacy.

Similar Private Companies By Industry

Company Name Region
DermaGenoma, Inc. United States
Innovative BioTherapies, Inc. United States
DTI Medical Corp. United States
Wellstat Biologics Corporation United States
Afferent Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cellectis Plant Sciences Inc, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.